For Bladder Cancer Patients Researchers Propose A Novel Prognostic Model For Disease-Specific Survival
Main Category: Urology / NephrologyAlso Included In: Cancer / Oncology
Article Date: 20 Mar 2013 - 0:00 PDT
For Bladder Cancer Patients Researchers Propose A Novel Prognostic Model For Disease-Specific Survival
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival (DSS) in bladder cancer (BCa) patients treated with radical cystectomy (RC).
This large series demonstrated that two types of pre-operative haematological disorders assessed by haemoglobin (Hb) and C-reacted protein (CRP) are independent prognostic indicators for patients with BCa treated by RC.
"Despite the wealth of evidence on the oncological significance of various clinico-pathological and molecular parameters for survival in invasive BCa patients treated with radical cystectomy, alterations of pre-operative haematological parameters have not been sufficiently addressed," write the authors of the study.
"The findings suggest that pre-operative Hb and CRP levels, which can be easily obtained during routine practice, provide additional independent prognostic information for DSS. Moreover, our risk stratification model, which combines both hematological and pathological parameters, may provide physicians with useful prognostic information for identifying patients who may be candidates for multimodal treatment, including innovative adjuvant treatments."
In the course of the study, the researchers performed a retrospective analysis of 249 consecutive BCa patients treated with RC without neoadjuvant therapy at several institutions.
Prognostic value of the pre-operative hematological laboratory parameters along with patient's clinico-pathological parameters were evaluated by univariate and multivariate Cox proportional hazard model analyses. Based on these data, the scientists developed a new scoring model to predict DSS after RC using the regression coefficients of the multivariate model.
One-, 3-, and 5-year DSS rates were 89.1%, 69.3%, and 62.7%, respectively. In multivariate analysis, pre-operative values of low hemoglobin (Hb) (< 10g /dL) and high C-reacted protein (CRP) (> 0.5 mg / dL), pathological T stage (≥ pT3a), lympho-vascular invasion (LVI) and positive surgical margin (PSM) status were independent factors for predicting poor prognosis. The score was calculated as 2 (if PSM) + 2 (Hb < 10g /dL) + 1 (if ≥ pT3a) + 1 (if LVI) + 1 (CRP > 0.5 mg / dL) and 0 (if otherwise).
The 4-year DSS in patients with a score in the ranges 0-1 (low-risk), 2-3 (intermediate-risk) and 4-7 (high-risk) was 83.4%, 48.8% and 5.9%, respectively All differences in DSS between subgroups were P < 0.0001.
Visit our urology / nephrology section for the latest news on this subject.
European Association of Urology
MLA
18 Jun. 2013. <http://www.medicalnewstoday.com/releases/257838.php>
APA
http://www.medicalnewstoday.com/releases/257838.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'For Bladder Cancer Patients Researchers Propose A Novel Prognostic Model For Disease-Specific Survival'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




